Anabolic steroid abuse and dependence in clinical practice

Physician and Sportsmedicine

Volumn 37, Issue 4, 2009, Pages 131-140

  Brower, Kirk J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Anabolic steroids; Androgens; Body dysmorphic disorder; Dependence; Psychiatric effects; Substance abuse treatment

Indexed keywords

ANABOLIC AGENT; ANDROGEN; FOLLITROPIN; LUTEINIZING HORMONE; TESTOSTERONE;

ALCOHOLISM; ANDROGEN DEFICIENCY; ARTICLE; ATHLETE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DEPENDENCE; DRUG SELF ADMINISTRATION; HUMAN; HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NONHUMAN; SUICIDAL IDEATION; WITHDRAWAL SYNDROME;

EID: 76149098831     PISSN: 00913847     EISSN: None     Source Type: Journal    
DOI: 10.3810/psm.2009.12.1751     Document Type: Article

References (87)

1. Quaglio G, Fornasiero A, Mezzelani P, Moreschini S, Lugoboni F, Lechi A. Anabolic steroids: dependence and complications of chronic use. Intern Emerg Med. 2009;4(4):289-296.
2. Thiblin I, Petersson A. Pharmacoepidemiology of anabolic androgenic steroids: a review. Fundam Clin Pharmacol. 2005;19(1):27-44.
3. Sjöqvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet. 2008;371(9627):1872- 1882.
4. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502-521.
5. Kanayama G, Hudson JI, Pope HG. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend. 2008;98(1-2):1-12.
6. Hoffman JR, Faigenbaum AD, Ratamess NA, Ross R, Kang J, Tenenbaum G. Nutritional supplementation and anabolic steroid use in adolescents. Med Sci Sports Exerc. 2008;40(1):15-24.
7. Bonetti A, Tirelli F, Catapano A, et al. Side effects of anabolic androgenic steroids abuse. Int J Sports Med. 2008;29(8):679-687.
8. Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med. 2004;32(2):534-542.
9. Talih F, Fattal O, Malone DJ. Anabolic steroid abuse: psychiatric and physical costs. Cleve Clin J Med. 2007;74(5):341-344.
10. Yesalis CE, Kennedy NJ, Kopstein AN, Bahrke MS. Anabolic-androgenic steroid use in the United States, JAMA. 1993;270(10):1217-1221.
11. Pope HG Jr, Brower KJ. Treatment of anabolic-androgenic steroid-related disorders. In: Galanter M, Kleber HD, eds. Textbook of Substance Abuse Treatment. 4th ed. Washington, DC: American Psychiatric Publishing; 2008:237-245.
12. Leone JE, Sedory EJ, Gray KA. Recognition and treatment of muscle dysmorphia and related body image disorders. J Athl Train. 2005;40(4): 352-359.
13. Tan RS, Vasudevan D. Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse. Fertil Steril. 2003;79(1): 203-205.
14. Menon DK. Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. Fertil Steril. 2003;79(suppl 3):1659-1661.
15. Frankle M, Leffers D. Athletes on anabolic-androgenic steroids: new approach diminishes health problems. Phys Sportsmed. 1992;20(6):75-87.
16. Corcoran JP, Longo EL. Psychological treatment of anabolic-androgenic steroid-dependent individuals. J Subst Abuse Treat. 1992;9(3):229-235.
17. Williamson K, Davies M, McBride A. A well-steroid user clinic. Druglink. 1992;15.
18. Brower KJ. Anabolic steroid abuse and dependence. Curr Psychiatry Rep. 2002;4(5):377-387.
19. Giannini AJ, Miller N, Kocjan DK. Treating steroid abuse: a psychiatric perspective. Clin Pediatr (Phila). 1991;30(9):538-542.
20. McAllister MS, Collins GB. Anabolic-androgenic steroid abuse by physicians. J Addict Dis. 2006;25(3):105-110.
21. Clancy GP, Yates WR. Anabolic steroid use among substance abusers in treatment. J Clin Psychiatry. 1992;53(3):97-100.
22. Kanayama G, Cohane GH, Weiss RD, Pope HG. Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? J Clin Psychiatry. 2003;64(2):156-160.
23. Pope HG, Kanayama G, Ionescu-Pioggia M, Hudson JI. Anabolic steroid users' attitudes towards physicians. Addiction. 2004;99(9):1189-1194.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
25. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr. Issues for DSM-V: clarifying the diagnostic criteria for anabolic-androgenic steroid dependence. Am J Psychiatry. 2009;166(6):642-645.
26. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. In press.
27. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91(6):1995-2010.
28. Millar AP. Licit steroid use-hope for the future. Br J Sports Med. 1994; 28(2):79-83.
29. Skarberg K, Nyberg F, Engstrom I. Multisubstance use as a feature of addiction to anabolic-androgenic steroids. Eur Addict Res. 2009;15(2): 99-106.
30. Calfee R, Fadale P. Popular ergogenic drugs and supplements in young athletes. Pediatrics. 2006;117(3):e577-e589.
31. Brown GA, Vukovich M, King DS. Testosterone prohormone supplements. Med Sci Sports Exerc. 2006;38(8):1451-1461.
32. Saugy M, Robinson N, Saudan C, Baume N, Avois L, Mangin P. Human growth hormone doping in sport. Br J Sports Med. 2006;40(suppl 1):i35-i39.
33. Striegel H, Simon P, Frisch S, et al. Anabolic ergogenic substance users in fitness-sports: a distinct group supported by the health care system. Drug Alcohol Depend. 2006;81(1):11-19.
34. Steensland P, Hallberg M, Kindlundh A, Fahlke C, Nyberg F. Amphetamine-induced aggression is enhanced in rats pre-treated with the anabolic androgenic steroid nandrolone decanoate. Steroids. 2005; 70(3):199-204.
35. Tan RS, Scally MC. Anabolic steroid-induced hypogonadism-towards a unified hypothesis of anabolic steroid action. Med Hypotheses. 2009;72(6):723-728.
36. Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc. 1995;27(9):1252-1262.
37. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis. 1998;41(1):1-15.
38. Payne J, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. Heart. 2004;90(5):473-475.
39. Modlinski R, Fields KB. The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands. Curr Sports Med Rep. 2006;5(2):104-109.
40. Socas L, Zumbado M, Perez-Luzardo O, et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med. 2005;39(5):e27.
41. Gorayski P, Thompson CH, Subhash HS, Thomas AC. Hepatocellular carcinoma associated with recreational anabolic steroid use. Br J Sports Med. 2008;42(1):74-75.
42. Bain J, Brock G, Kuzmarov I. Canadian Society for the Study of the Aging Male: response to health Canada's position paper on testosterone treatment. J Sex Med. 2007;4(3):558-566.
43. Petersson A, Garle M, Granath F, Thiblin I. Convulsions in users of anabolic androgenic steroids: possible explanations. J Clin Psychopharmacol. 2007;27(6):723-725.
44. Rogol AD, Martha PM Jr, Blizzard RM. Anabolic-androgenic steroids profoundly affect growth at puberty in boys. NIDA Res Monogr. 1990;102:187-195.
45. Trenton AJ, Currier GW. Behavioural manifestations of anabolic steroid use. CNS Drugs. 2005;19(7):571-595.
46. Hall RC, Chapman MJ. Psychiatric complications of anabolic steroid abuse. Psychosomatics. 2005;46(4):285-290.
47. Genazzani AR, Pluchino N, Freschi L, Ninni F, Luisi M. Androgens and the brain. Maturitas. 2007;57(1):27-30.
48. Clark AS, Henderson LP. Behavioral and physiological responses to anabolic-androgenic steroids. Neurosci Biobehav Rev. 2003;27(5): 413-436.
49. Kanayama G, Amiaz R, Seidman S, Pope HG. Testosterone supplementation for depressed men: current research and suggested treatment guidelines. Exp Clin Psychopharmacol. 2007;15(6):529-538.
50. Beauchet O. Testosterone and cognitive function: current clinical evidence of a relationship. Eur J Endocrinol. 2006;155(6):773-781.
51. Janowsky JS. Thinking with your gonads: testosterone and cognition. Trends Cogn Sci. 2006;10(2):77-82.
52. Hajszan T, MacLusky NJ, Johansen JA, Jordan CL, Leranth C. Effects of androgens and estradiol on spine synapse formation in the prefrontal cortex of normal and testicular feminization mutant male rats. Endocrinology. 2007;148(5):1963-1967.
53. Spritzer MD, Galea LA. Testosterone and dihydrotestosterone, but not estradiol, enhance survival of new hippocampal neurons in adult male rats. Dev Neurobiol. 2007;67(10):1321-1333.
54. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. Eur Psychiatry. 2006;21(8):551-562.
55. Malone DA Jr, Dimeff RJ, Lombardo JA, Sample RH. Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users, Clin J Sport Med. 1995;5(1):25-31.
56. Thiblin I, Runeson B, Rajs J. Anabolic androgenic steroids and suicide. Ann Clin Psychiatry. 1999;11(4):223-231.
57. Klotz F, Petersson A, Isacson D, Thiblin I. Violent crime and substance abuse: a medico-legal comparison between deceased users of anabolic androgenic steroids and abusers of illicit drugs. Forensic Sci Int. 2007;173(1):57-63.
58. Petersson A, Garle M, Holmgren P, Druid H, Krantz P, Thiblin I. Toxicological findings and manner of death in autopsied users of anabolic androgenic steroids. Drug Alcohol Depend. 2006;81(3):241-249.
59. Elofson G, Elofson S. Steroids claimed our son's life. Phys Sportsmed. 1990;18:15-16.
60. Vjorkqvist KT, Bjorklund AC, Bjorkqvist SE. Testosterone intake and aggressiveness: real effect of anticipation. Aggress Behav. 1994;20:17-26.
61. Bahrke MS, Yesalis CE 3rd, Wright JE. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update. Sports Med. 1996;22(6):367-390.
62. Thiblin I, Mobini-Far H, Frisk M. Sudden unexpected death in a female fitness athlete, with a possible connection to the use of anabolic androgenic steroids (AAS) and ephedrine. Forensic Sci Int. 2009;184(1-3):e7-e11.
63. Thiblin I, Lindquist O, Rajs J. Cause and manner of death among users of anabolic androgenic steroids. J Forensic Sci. 2000;45(1):16-23.
64. Perry PJ, Lund BC, Deninger MJ, Kutscher EC, Schneider J. Anabolic steroid use in weightlifters and bodybuilders: an internet survey of drug utilization. Clin J Sport Med. 2005;15(5):326-330.
65. Kanayama G, Hudson JI, Pope HG Jr. Features of men with anabolic-androgenic steroid dependence: A comparison with nondependent AAS users and with AAS nonusers. Drug Alcohol Depend. 2009;102(1-3):130-137.
66. Fudala PJ, Weinrieb RM, Calarco JS, Kampman KM, Boardman C. An evaluation of anabolic-androgenic steroid abusers over a period of 1 year: seven case studies. Ann Clin Psychiatry. 2003;15(2):121-130.
67. Wood RI. Anabolic-androgenic steroid dependence? Insights from animals and humans. Front Neuroendocrinol. 2008;29(4):490-506.
68. Peters KD, Wood RI. Androgen dependence in hamsters: overdose, tolerance, and potential opioidergic mechanisms. Neuroscience. 2005; 130(4):971-981.
69. Wood RI. Anabolic steroids: a fatal attraction? J Neuroendocrinol. 2006; 18(3):227-228.
70. Birgner C, Kindlundh-Hogberg AM, Nyberg F, Bergstrom L. Altered extracellular levels of DOPAC and HVA in the rat nucleus accumbens shell in response to sub-chronic nandrolone administration and a subsequent amphetamine challenge. Neurosci Lett. 2007;412(2):168-172.
71. Hurst R, Hale B, Smith D, Collins D. Exercise dependence, social physique anxiety, and social support in experienced and inexperienced bodybuilders and weightlifters. Br J Sports Med. 2000;34(6):431-435.
72. Armsey TD, Hosey RG. Medical aspects of sports: epidemiology of injuries, preparticipation physical examination, and drugs in sports. Clin Sports Med. 2004;23(2):255-279.
73. Pope HG, Gruber AJ, Choi P, Olivardia R, Phillips KA. Muscle dysmorphia. An underrecognized form of body dysmorphic disorder. Psychosomatics. 1997;38(6):548-557.
74. Grieve FG. A conceptual model of factors contributing to the development of muscle dysmorphia. Eat Disord. 2007;15(1):63-80.
75. Baum A. Eating disorders in the male athlete. Sports Med. 2006;36(1):1-6.
76. Chung B. Muscle dysmorphia: a critical review of the proposed criteria. Perspect Biol Med. 2001;44(4):565-574.
77. Rohman L. The relationship between anabolic androgenic steroids and muscle dysmorphia: a review. Eat Disord. 2009;17(3):187-199.
78. Ray R, Wiese-Bjornstal DM, eds. Counseling in Sports Medicine. Champaign, IL: Human Kinetics; 1999.
79. Spector ND, Chanoine P. Hypertension, sports supplements and motivational interviewing. Curr Opin Pediatr. 2007;19(6):726-732.
80. Hettema J, Steele J, Miller WR. Motivational interviewing. Annu Rev Clin Psychol. 2005;1:91-111.
81. Collins GB, Pippenger CE, Janesz JW. Links in the chain: an approach to the treatment of drug abuse on a professional football team. Cleveland Clinical Quarterly. 1984;51:485-492.
82. Malone DA Jr, Dimeff RJ. The use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series. J Clin Psychiatry. 1992;53:130-132.
83. Malone DA Jr, Dimeff RJ. The use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series. J Clin Psychiatry. 1992;53(4):130-132.
84. Brower KJ. Withdrawal from anabolic steroids. Curr Ther Endocrinol Metab. 1997;6:338-343.
85. Jarow JP, Lipshultz LI. Anabolic steroid-induced hypogonadotropic hypogonadism. Am J Sports Med. 1990;18(4):429-431.
86. American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders, second edition. Am J Psychiatry. 2007;164(4 Suppl):5-123.
87. Yesalis CE. Winning and performance-enhancing drugs-our dual addiction. Phys Sportsmed. 1990;18:161-167.